Upgrade to SI Premium - Free Trial

MetaVia (MTVA)

1.60 -0.11 (6.43%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/18/26)

Latest Headlines

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum June 17, 2026 8:31 AM - PR NewsWire Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream June 10, 2026 7:00 AM - Globe NewsWire BioStem Technologies appoints three new board members June 9, 2026 7:00 AM - StreetInsider BioStem Technologies Announces Appointment of Three New Members to its Board of Directors June 9, 2026 7:00 AM - Globe NewsWire Form 4 MetaVia Inc. For: Jun 08 Filed by: Tursi James Patrick June 8, 2026 6:34 PM - SEC Filing Form 4 MetaVia Inc. For: Jun 08 Filed by: STRICKLAND D GORDON June 8, 2026 6:33 PM - SEC Filing Form 4 MetaVia Inc. For: Jun 08 Filed by: Salsbury Michael June 8, 2026 6:32 PM - SEC Filing Form 4 MetaVia Inc. For: Jun 08 Filed by: GROVES JASON L June 8, 2026 6:31 PM - SEC Filing Form 4 MetaVia Inc. For: Jun 08 Filed by: KOVEN ANDREW I June 8, 2026 6:31 PM - SEC Filing Form 4 MetaVia Inc. For: Jun 08 Filed by: Glickman Mark A June 8, 2026 6:29 PM - SEC Filing Form S-8 MetaVia Inc. June 8, 2026 4:31 PM - SEC Filing MetaVia stockholders approve reverse stock split, equity plan expansion June 8, 2026 4:04 PM - StreetInsider Form 8-K MetaVia Inc. For: Jun 08 June 8, 2026 4:01 PM - SEC Filing Form 8-K MetaVia Inc. For: Jun 08 June 8, 2026 9:02 AM - SEC Filing MetaVia reports obesity drug achieves 9.1% weight loss in phase 1 study June 8, 2026 8:32 AM - StreetInsider MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential June 8, 2026 8:31 AM - PR NewsWire MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference June 4, 2026 8:31 AM - PR NewsWire Form 8-K MetaVia Inc. For: May 27 May 27, 2026 9:01 AM - SEC Filing MetaVia reports 9.1% weight loss in obesity drug trial May 27, 2026 8:31 AM - StreetInsider MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH May 27, 2026 8:31 AM - PR NewsWire MetaVia announces peer-reviewed study on vanoglipel for liver fibrosis May 20, 2026 8:02 AM - StreetInsider MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH May 20, 2026 8:00 AM - PR NewsWire Form 8-K MetaVia Inc. For: May 18 May 18, 2026 9:01 AM - SEC Filing MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions May 18, 2026 8:31 AM - PR NewsWire Form SCHEDULE 13G MetaVia Inc. Filed by: Alyeska Investment Group, L.P. May 15, 2026 4:45 PM - SEC Filing Form 10-Q MetaVia Inc. For: Mar 31 May 14, 2026 4:09 PM - SEC Filing Form 8-K MetaVia Inc. For: May 14 May 14, 2026 4:07 PM - SEC Filing MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update May 14, 2026 4:05 PM - PR NewsWire Form 8-K MetaVia Inc. For: May 11 May 11, 2026 9:01 AM - SEC Filing MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 May 11, 2026 8:31 AM - PR NewsWire Form ARS MetaVia Inc. For: Dec 31 April 27, 2026 6:06 AM - SEC Filing Form DEF 14A MetaVia Inc. For: Jun 08 April 27, 2026 6:04 AM - SEC Filing Form PRE 14A MetaVia Inc. For: Jun 08 April 15, 2026 4:02 PM - SEC Filing Form 8-K MetaVia Inc. For: Apr 10 April 10, 2026 8:46 AM - SEC Filing MetaVia begins higher-dose phase 1 trial of obesity drug DA-1726 April 10, 2026 8:30 AM - StreetInsider MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity April 10, 2026 8:30 AM - PR NewsWire Form 424B3 MetaVia Inc. April 7, 2026 4:02 PM - SEC Filing Form EFFECT MetaVia Inc. April 7, 2026 12:34 PM - SEC Filing Form S-8 MetaVia Inc. April 3, 2026 4:04 PM - SEC Filing Form POS AM MetaVia Inc. April 3, 2026 4:01 PM - SEC Filing MetaVia (MTVA) PT Lowered to $20 at H.C. Wainwright March 30, 2026 6:45 AM - StreetInsider MetaVia (MTVA) PT Lowered to $20 at H.C. Wainwright March 27, 2026 12:18 PM - StreetInsider Form 8-K MetaVia Inc. For: Mar 26 March 26, 2026 4:31 PM - SEC Filing Form 10-K MetaVia Inc. For: Dec 31 March 26, 2026 8:47 AM - SEC Filing Form 8-K MetaVia Inc. For: Mar 26 March 26, 2026 8:31 AM - SEC Filing MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update March 26, 2026 8:31 AM - PR NewsWire Full Article List